KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Accumulated Expenses (2016 - 2025)

Fulgent Genetics' Accumulated Expenses history spans 10 years, with the latest figure at $23.0 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses changed N/A year-over-year to $23.0 million; the TTM value through Sep 2025 reached $23.0 million, changed N/A, while the annual FY2024 figure was $24.3 million, 322.91% up from the prior year.
  • Accumulated Expenses for Q3 2025 was $23.0 million at Fulgent Genetics, up from $7.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $27.1 million in Q2 2022 and bottomed at $5.7 million in Q4 2023.
  • The 5-year median for Accumulated Expenses is $21.7 million (2023), against an average of $19.3 million.
  • The largest annual shift saw Accumulated Expenses plummeted 77.02% in 2023 before it soared 322.91% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $17.7 million in 2021, then skyrocketed by 41.22% to $25.0 million in 2022, then tumbled by 77.02% to $5.7 million in 2023, then skyrocketed by 322.91% to $24.3 million in 2024, then dropped by 5.23% to $23.0 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Accumulated Expenses are $23.0 million (Q3 2025), $7.6 million (Q2 2025), and $24.3 million (Q4 2024).